Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Eucrates Biomedical Acquisition Corp. | 2,619,906 | reported | 24 Nov 2020 | tx 1−255,094 |
| EXELIXIS, INC. | 1,197,595 | reported | 27 May 2026 | tx 109+1,555,883−974,715 |
| Ovid Therapeutics Inc. | 65,000 | reported | 26 Feb 2026 | tx 2+155,000 |
| ANADYS PHARMACEUTICALS INC | 15,000 | reported | 27 May 2011 | tx 15+524,304 |
| GENVEC INC | 15,000 | reported | 22 Jun 2006 | tx 2+30,000 |
| BIOGEN INC. | 10,095 | reported | 15 Jun 2022 | tx 32+133,635−95,370 |
| BG Medicine, Inc. | 5,000 | reported | 18 Nov 2015 | tx 54+1,216,384−1,608,203 |
| SGX PHARMACEUTICALS, INC. | 0 | reported | 06 Feb 2006 | tx 4+35,930−71,860 |
| DIACRIN INC /DE/ | 0 | reported | 21 Aug 2003 | tx 6−248,000 |
| Regulus Therapeutics Inc. | 0 | reported | 25 Jun 2025 | tx 67+11,266,361−1,561,596 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 27 May 2026 | GRANT_AWARD | EXELIXIS, INC. | 8,367 | 0.00 USD | |
| 26 Feb 2026 | GRANT_AWARD | Ovid Therapeutics Inc. | 65,000 | 0.00 USD | deriv |
| 12 Nov 2025 | SALE | EXELIXIS, INC. | 100,000 | 43.55 USD | |
| 25 Jun 2025 | TENDER | Regulus Therapeutics Inc. | 976,253 | — | |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 64,635 | — | |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 59,514 | — | deriv |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 60,000 | — | deriv |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 30,000 | — | deriv |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 30,000 | — | deriv |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 9,000 | — | deriv |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 4,000 | — | deriv |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 2,325 | — | deriv |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 4,650 | — | deriv |
| 25 Jun 2025 | OTHER | Regulus Therapeutics Inc. | 15,000 | — | deriv |
| 29 May 2025 | GRANT_AWARD | EXELIXIS, INC. | 9,812 | 0.00 USD | |
| 15 May 2025 | EXERCISE | EXELIXIS, INC. | 20,634 | 19.77 USD | |
| 15 May 2025 | SALE | EXELIXIS, INC. | 15,874 | 44.35 USD | |
| 15 May 2025 | EXERCISE | EXELIXIS, INC. | 15,874 | 20.50 USD | |
| 15 May 2025 | SALE | EXELIXIS, INC. | 20,634 | 44.35 USD | |
| 15 May 2025 | EXERCISE | EXELIXIS, INC. | 15,874 | 0.00 USD | deriv |
| 15 May 2025 | EXERCISE | EXELIXIS, INC. | 20,634 | 0.00 USD | deriv |
| 30 Apr 2025 | GRANT_AWARD | Regulus Therapeutics Inc. | 62,500 | 0.00 USD | |
| 03 Mar 2025 | GRANT_AWARD | Ovid Therapeutics Inc. | 90,000 | 0.00 USD | deriv |
| 31 May 2024 | GRANT_AWARD | EXELIXIS, INC. | 18,838 | 0.00 USD | |
| 20 May 2024 | EXERCISE | EXELIXIS, INC. | 11,686 | 19.57 USD |
7 purchases reported after at least 12 months of silence — most recent on 15 Nov 2018.